Summary
SPDR Gold Trust (GLD) reported strong performance for the quarter ending December 31, 2023, driven by a significant increase in the fair value of its gold holdings. The Trust's net assets grew to $58.27 billion, up from $52.52 billion at the end of the previous quarter. This growth was primarily fueled by a substantial unrealized gain on its gold investments, reflecting the rising price of gold. The Net Asset Value (NAV) per Share increased to $191.12 from $173.51, indicating positive returns for shareholders. Operationally, the Trust saw a net increase in shares outstanding due to higher creation activity compared to redemptions, signifying investor demand. Total expenses remained stable and are consistent with the Trust's expense ratio, which is managed to track the performance of gold bullion. The Trust continues to hold 100% allocated gold bullion, with no exposure to derivative instruments, aligning with its objective of providing direct market exposure to gold prices.
Financial Highlights
10 data points| Operating Expenses | $55.75M |
| Net Income | $5.27B |
| EPS (Basic) | $17.44 |
| Shares Outstanding (Basic) | 302.25M |
Key Highlights
- 1Net assets increased by approximately 10.95% to $58.27 billion as of December 31, 2023, from $52.52 billion as of September 30, 2023.
- 2Net Asset Value (NAV) per Share rose significantly to $191.12 from $173.51 in the prior quarter, reflecting strong performance driven by gold price appreciation.
- 3The Trust experienced a net increase in Shares outstanding, with 304.9 million Shares outstanding at December 31, 2023, compared to 302.7 million at September 30, 2023, indicating net inflows.
- 4Total net income for the quarter was $5.27 billion, a substantial increase from $4.03 billion in the same period of the previous year, primarily due to gains on gold investments.
- 5The Trust's investments consist entirely of gold bullion, valued at $58.46 billion at quarter-end, representing 100.33% of net assets.
- 6Total expenses for the quarter were $55.75 million, consistent with the Trust's expense ratio of 0.40%.